These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 15243520

  • 21. Evolution of clinical and molecular responses to bexarotene treatment in cutaneous T-cell lymphoma.
    Ballanger F, Nguyen JM, Khammari A, Dréno B.
    Dermatology; 2010; 220(4):370-5. PubMed ID: 20484880
    [Abstract] [Full Text] [Related]

  • 22. Therapeutic advances in cutaneous T-cell lymphoma (CTCL): from retinoids to rexinoids.
    Stadler R, Kremer A.
    Semin Oncol; 2006 Feb; 33(1 Suppl 3):S7-10. PubMed ID: 16516669
    [Abstract] [Full Text] [Related]

  • 23. Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma.
    Aviles A, Neri N, Fernandez-Diez J, Silva L, Nambo MJ.
    Hematology; 2015 Oct; 20(9):538-42. PubMed ID: 25592781
    [Abstract] [Full Text] [Related]

  • 24. Prognostic value of blood eosinophilia in primary cutaneous T-cell lymphomas.
    Tancrède-Bohin E, Ionescu MA, de La Salmonière P, Dupuy A, Rivet J, Rybojad M, Dubertret L, Bachelez H, Lebbé C, Morel P.
    Arch Dermatol; 2004 Sep; 140(9):1057-61. PubMed ID: 15381544
    [Abstract] [Full Text] [Related]

  • 25. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
    Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R.
    Oncologist; 2007 Oct; 12(10):1247-52. PubMed ID: 17962618
    [Abstract] [Full Text] [Related]

  • 26. Bexarotene: a clinical review.
    Farol LT, Hymes KB.
    Expert Rev Anticancer Ther; 2004 Apr; 4(2):180-8. PubMed ID: 15056048
    [Abstract] [Full Text] [Related]

  • 27. Phase I/II study of the oral retinoid X receptor agonist bexarotene in Japanese patients with cutaneous T-cell lymphomas.
    Hamada T, Sugaya M, Tokura Y, Ohtsuka M, Tsuboi R, Nagatani T, Tani M, Setoyama M, Matsushita S, Kawai K, Yonekura K, Yoshida T, Saida T, Iwatsuki K.
    J Dermatol; 2017 Feb; 44(2):135-142. PubMed ID: 27543197
    [Abstract] [Full Text] [Related]

  • 28. Folliculotropic mycosis fungoides: an aggressive variant of cutaneous T-cell lymphoma.
    Gerami P, Rosen S, Kuzel T, Boone SL, Guitart J.
    Arch Dermatol; 2008 Jun; 144(6):738-46. PubMed ID: 18559762
    [Abstract] [Full Text] [Related]

  • 29. Bexarotene ligand pharmaceuticals.
    Hurst RE.
    Curr Opin Investig Drugs; 2000 Dec; 1(4):514-23. PubMed ID: 11249708
    [Abstract] [Full Text] [Related]

  • 30. Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy.
    Querfeld C, Rosen ST, Kuzel TM, Kirby KA, Roenigk HH, Prinz BM, Guitart J.
    Arch Dermatol; 2005 Mar; 141(3):305-11. PubMed ID: 15781671
    [Abstract] [Full Text] [Related]

  • 31. Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion.
    Assaf C, Bagot M, Dummer R, Duvic M, Gniadecki R, Knobler R, Ranki A, Schwandt P, Whittaker S.
    Br J Dermatol; 2006 Aug; 155(2):261-6. PubMed ID: 16882161
    [Abstract] [Full Text] [Related]

  • 32. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results.
    Duvic M, Hymes K, Heald P, Breneman D, Martin AG, Myskowski P, Crowley C, Yocum RC, Bexarotene Worldwide Study Group.
    J Clin Oncol; 2001 May 01; 19(9):2456-71. PubMed ID: 11331325
    [Abstract] [Full Text] [Related]

  • 33. Bexarotene (Targretin) for cutaneous T-cell lymphoma.
    Med Lett Drugs Ther; 2000 Apr 03; 42(1075):31-2. PubMed ID: 10788961
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides).
    Kessler JF, Jones SE, Levine N, Lynch PJ, Booth AR, Meyskens FL.
    Arch Dermatol; 1987 Feb 03; 123(2):201-4. PubMed ID: 2949706
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Topical and oral bexarotene.
    Schadt CR.
    Dermatol Ther; 2013 Feb 03; 26(5):400-3. PubMed ID: 24099070
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.